Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...